A meta-analysis of 21 trials and nearly 26,000 patients found semaglutide reduced atrial fibrillation risk by 30%, with the strongest effects in diabetes patients and with oral semaglutide.
30% AFib reductionacross 21 randomized trials and 25,957 patients, with oral semaglutide showing an even greater 51% reduction
What the researchers found
Semaglutide reduced atrial fibrillation occurrence by 30% overall (RR 0.70, 95% CI 0.52-0.95), with subgroup benefits of 51% reduction with oral semaglutide and 29% in T2DM patients.
Why it matters
Atrial fibrillation increases stroke risk five-fold and affects millions worldwide. If semaglutide prevents AFib in addition to its diabetes and weight benefits, this represents a major additional cardiovascular protection for the millions already taking it.
The numbers in context
Meta-analysis pooled randomized controlled trials through December 2023 examining AF incidence in semaglutide versus control groups.
How the study worked
Systematic review and meta-analysis of 21 randomized controlled trials (25,957 patients) from MEDLINE, EMBASE, Cochrane CENTRAL, and clinicaltrials.gov through December 2023. Calculated relative risks with 95% CIs for overall population and subgroups.
Who was studied
Pooled RCT data of patients with T2DM and/or obesity receiving semaglutide
What this study cannot tell us
AFib was a secondary or safety endpoint in the included trials, not the primary focus. The benefit did not reach significance vs placebo alone (RR 0.77, CI 0.56-1.07) or in obesity-only patients. Different trial designs, populations, and follow-up durations were pooled. A dedicated AFib prevention trial would provide stronger evidence.
How to read the evidence
Strong evidence: systematic review and meta-analysis of 21 RCTs, though AFib was not the primary endpoint in any included trial and some subgroup analyses were not statistically significant.
When this study was published
Published in 2024 with data through December 2023. Reflects the most comprehensive AFib analysis of semaglutide trials to date.
The bigger picture
The cardiovascular benefits of GLP-1 drugs keep expanding — from heart failure to atherosclerotic disease, and now potentially atrial fibrillation. If confirmed in dedicated AFib trials, semaglutide could become a multi-purpose cardiovascular protection drug, adding rhythm control to its already impressive list of metabolic and cardiac benefits.
Questions still open
- Why did oral semaglutide show a stronger AFib reduction than subcutaneous semaglutide?
- Would a dedicated randomized trial of semaglutide for AFib prevention confirm these meta-analytic findings?
- Does semaglutide reduce AFib through weight loss, anti-inflammatory effects, direct cardiac effects, or a combination?
Common questions
Can semaglutide prevent atrial fibrillation?
Why might oral semaglutide work better than injectable for AFib?
Read the original research
Semaglutide for the prevention of atrial fibrillation: A systematic review and meta-analysis.
Diabetes & metabolic syndrome, 18(6), 103067
Citation
Zhang, Hong-Da; Ding, Lei; Liu, Ke; Mi, Li-Jie; Zhang, Ai-Kai; Yu, Feng-Yuan; Yan, Xin-Xin; Peng, Fu-Hua; Shen, Yu-Jing; Tang, Min. (2024). Semaglutide for the prevention of atrial fibrillation: A systematic review and meta-analysis.. Diabetes & metabolic syndrome, 18(6), 103067. https://doi.org/10.1016/j.dsx.2024.103067